| Analysis of K-ras oncogene mutations in chronic pancreatitis with ductal hyperplasia. | None |
| Activation of the p21(Waf1/Cip1) promoter by the ets oncogene family transcription factor E1AF. | None |
| Inhibition of oncogenic and activated wild-type ras-p21 protein-induced oocyte maturation by peptides from the ras-binding domain of the raf-p74 protein, identified from molecular dynamics calculations. | None |
| Quantitative enriched PCR (QEPCR), a highly sensitive method for detection of K-ras oncogene mutation. | None |
| Subunit peptide cancer vaccines targeting activating mutations of the p21 ras proto-oncogene. | None |
| Differential binding to frequent HLA-A alleles of p21 RAS derived peptides bearing oncogenic substitutions at position 12 or 13. | None |
| [Expression of ras P21 oncoprotein in Syrian golden hamster embryo cells transformation induced by water pollutants]. | None |
| [Sequencing analysis of human K-ras oncogene exon 1 in Chinese people]. | None |
| K-ras oncogene mutations indicate malignancy in cystic tumors of the pancreas. | None |
| Plasma Asp13-Ki-ras oncoprotein expression in vinyl chloride monomer workers in Taiwan. | None |
| Modulation of ras p21 oncoprotein levels and DNA strand breakage in human cells with chemotherapeutic agents and/or deferoxamine. | None |